Is Vladonix FDA approved?
No. This profile records Vladonix as not FDA approved and for research use only.
MORE CONTEXT ›
Review the regulatory and source details on this page for the current context.
THE OVARIAN RESTORER
A-6 Thymus Bioregulator Peptide
Vladonix is a bioregulator peptide derived from thymus tissue that restores immune balance during aging. It supports T-cell maturation and differentiation, reduces chronic inflammation, and strengthens your body's defense mechanisms. Particularly valuable for people experiencing immune decline with age.
Not FDA approved · research use only
Reviewed by our clinical team
1 research sources
Aug 28, 2026
Dose and schedule recommendations shown below come from The Peptide App Clinical Team. Research links are provided so readers can inspect the supporting evidence directly. Review the sources.
No. This profile records Vladonix as not FDA approved and for research use only.
Review the regulatory and source details on this page for the current context.
Dose: 20 mg daily (oral or sublingual).
Schedule: daily. Cycle: 4 weeks on, 12 weeks off. This is clinical-team guidance for reference and does not replace individualized instructions from a licensed clinician.
This guide links to 1 curated or current research sources.
Open the research section to inspect the source titles, publication details, study types, and available abstracts directly.
Promotes FOXN1 and AIRE expression for proper T-cell education
Reduces TNF-α, IL-1β, IL-6 while increasing IL-10 and TGF-β1
Enhances perforin and granzyme B in cytotoxic cells
The live research feed did not return papers for this page. The curated references below remain available for crawlable source context.